Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

Ginkgo Bioworks Holdings, Inc., a leader in cell programming and biosecurity, has released its financial results for the second quarter ending June 30, 2025. The company has provided a comprehensive update on its restructuring efforts, including the achievement of its expanded $250 million cost savings target.

Financial Highlights

For the second quarter of 2025, Ginkgo Bioworks reported total revenue of $50 million, a decrease from $56 million in the same period last year. The company's Cell Engineering revenue increased by 8% to $39 million, driven by growth in biopharma and government customers. However, Biosecurity revenue saw a significant decline, dropping to $10 million from $20 million in the prior year period.

The company reported a GAAP net loss of $(60) million, a notable improvement from the $(217) million loss in the comparable period last year. Adjusted EBITDA also showed improvement, with a loss of $(28) million compared to $(99) million in the previous year, primarily due to a decrease in operating expenses. As of June 30, 2025, Ginkgo Bioworks had a cash, cash equivalents, and marketable securities balance of $474 million.

Business and Operational Highlights

Ginkgo Bioworks continues to make strides in its Automation and Datapoints offerings, which are becoming essential tools in AI-powered bioengineering. Notably, the Pacific Northwest National Laboratory (PNNL) selected Ginkgo Automation to deliver a state-of-the-art automated anaerobic phenotyping platform. Additionally, Ginkgo launched a new in vitro ADME profiling service and its first direct-to-scientist product, a cell-free protein synthesis system.

Strategic Initiatives and Corporate Developments

The company has achieved its $250 million annualized cost-reduction goal three months ahead of schedule, thanks to reductions in force and other cost-cutting measures. Site consolidation efforts were substantially completed by the end of 2024, with excess space available for sublease.

Management's Perspective

Jason Kelly, co-founder and CEO of Ginkgo Bioworks, highlighted the growing demand for the company's automation and data generation capabilities, which are driving commercial traction, including major new government contracts and expanded service offerings in the biopharma industry. Kelly emphasized the company's rigorous financial discipline, which has enabled them to achieve their cost-reduction goals ahead of schedule.

Future Outlook

Ginkgo Bioworks reaffirmed its full-year 2025 revenue guidance of $167-$187 million. The company expects Cell Engineering revenue to be between $117-$137 million and Biosecurity revenue to be at least $40 million. Ginkgo continues to progress towards its objective of reaching Adjusted EBITDA breakeven by the end of 2026.

SEC Filing: Ginkgo Bioworks Holdings, Inc. [ DNA ] - 8-K - Aug. 07, 2025